Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary
Related Experiment Video
Updated: Oct 21, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Ryuta Miyake1, Shoichiro Yamanaka1, Sho Matsubara1
1Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan.
Background/Aim:
To evaluate the antitumor effects of Plitidepsin against clear cell carcinoma (CCC) of the ovary.
Materials And Methods:
The expression of eEF1A2 in ovarian cancer was assessed by immunohistochemistry. Using ovarian CCC cell lines, the antitumor effect of Plitidepsin was assessed both in vitro and in vivo. By over-expressing or knocking down the eEF1A2 expression, we investigated the role of eEF1A2 in the sensitivity of CCC cells to Plitidepsin.
Results:
Immunoreactivity to eEF1A2 was observed in 76.2% of CCC, which was significantly higher than other histological subtypes of ovarian cancer. Plitidepsin exhibited significant antitumor activity toward chemonaive and chemoresistant CCC cells both in vitro and in vivo. Ectopic expression of eEF1A2 in CCC cells resulted in increased sensitivity to Plitidepsin. In contrast, eEF1A2 knockdown decreased sensitivity of CCC cells to plitidepsin.
Conclusion:
Plitidepsin, a novel anti-cancer agent that targets eEF1A2, may be a promising agent for treating ovarian CCC.
